NRF2の全身活性化は,臨床的に承認されたKRAS- G12C抗がん剤の治療効果に貢献する.
PubMedで要約を見る
まとめ
この要約は機械生成です。KRAS<sup>G12C</sup>阻害剤であるソトラジブとアダグラジブは,通常薬剤耐性に関連するタンパク質であるNRF2を意外に活性化させます. このNRF2誘導は抗がん免疫を強化し,
科学分野
- 腫瘍学
- 分子生物学
- 免疫学
背景
- 腫瘍性KRAS変異,特にKRAS<sup>G12C</sup>は,様々な癌の主要な原動力であり,歴史的に重要な治療上の課題となっている.
- KEAP1- NRF2経路の共変異は,KRAS変異性肺がんにおいて一般的であり,NRF2の活性化が抗がん療法に対する抵抗の既知のメカニズムである.
研究 の 目的
- KRAS<sup>G12C</sup>阻害剤に対する臨床反応に対する異常NRF2活性化の影響を調査する.
- KRAS<sup>G12C</sup>阻害剤とNRF2調節剤のメカニズム的関連を解明する.
主な方法
- 遺伝子ノックアウトを使って NRF2経路の変異を研究した.
- 細胞反応を分析するために単細胞RNA配列化 (scRNA-seq) を採用した.
- 表面プラズモン共鳴 (SPR) を適用して,薬物標的の相互作用を決定する.
主要な成果
- 臨床的に承認されたKRAS<sup>G12C</sup>阻害剤であるSotorasibとAdagrasibは,生理学的に重要な濃度でNRF2を誘導することが判明しました.
- これらの薬の電離性特性により,KRAS<sup>G12C</sup>を阻害し,KEAP1のシステインセンサーに結合し,NRF2依存遺伝子発現を上調する.
結論
- KRAS<sup>G12C</sup>阻害剤は,しばしば腫瘍生成と薬剤耐性を伴うタンパク質であるNRF2を正面に調節する新しい抗癌剤のクラスを表しています.
- これらの阻害剤によるNRF2活性化は,腫瘍と免疫細胞の両方の抗癌免疫力を高め,臨床効果に貢献します.
- このNRF2の全局的誘導は,現在進行中の臨床試験における併用療法と患者選択に重大な臨床的影響を及ぼします.
関連する概念動画
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

